Flattening of a Treatment-Resistant Retinal Pigment Epithelial Detachment After a Single Intravitreal Injection of Ziv-Aflibercept

Abstract

Intravitreal ziv-aflibercept safely and effectively improved a treatment-resistant PED. Intravitreal ziv-aflibercept could become a treatment option for neovascular age-related macular degeneration in countries where aflibercept (Eylea) is not available or its cost is prohibitive, but further studies are necessary to establish efficacy and safety.

Ziv‐aflibercept: A cost‐effective, off‐label, highly potent antagonist of vascular endothelial growth factor

“…The first reported human use of intravitreal ziv-aflibercept resulted in successful treatment of a patient with refractory neovascular age-related macular degeneration (nAMD) (de Oliveira Dias et al 2015) and this was soon followed by a pilot study of four patients with nAMD and two patients with diabetic macular oedema (DME) (Mansour et al 2015). Based on the encouraging results of this pilot study, several prospective short-term and long-term studies (Figs 2-5) with monthly injections (de Andrade et al 2018), treat-and-extend (Mansour et al 2019a) or pro re nata (Eldeeb et al 2017;de Oliveira Dias et al 2019) regimens have been performed in the following countries: Brazil (Andrade et al 2016;de Oliveira Dias et al 2016;de Oliveira Dias et al 2019); Egypt (Ashraf et al 2017a); India (Videkar et al 2015;Chhablani et al 2016Chhablani et al , 2017Yogi et al 2017); Iran (Baghi et al 2017, Jabbarpoor Bonyadi et al 2018HodjatJalali et al 2017); Lebanon (Mansour et al 2015); Mexico (Hernandez-Da Mota et al 2019); Switzerland (Doepfner et al 2018), Syria (Marashi 2016); and the United States (Aleman et al 2019…”